Dr. Thomas Wilckens is a medical doctor and a serial entrepreneur. He serves as the CEO of InnVentis Ltd., with a focus on the convergence of multi-omics technologies with real-world clinical data and machine learning to enable Precision Medicine
. The InnVentis technology platform combines data of unprecedented quality and depth with cutting-edge algorithms to create actionable insights such as cost-efficient sourcing of extremely high quality *omics analytics and clinical analytics, proprietary knowledge in machine learning and algorithm development, and stringent control of sample and data collection with proprietary standard operation procedures. Dr. Wilckens is also the founder of the LinkedIn group Precision Medicine Insight
. Thomas is also an associate at deep innovation GmbH, a boutique consultancy and spin-off of Vodafone Group R&D Germany. In 1998 he founded a drug discovery company as CEO/CSO with a focus on inflammatory and metabolic diseases. Thomas obtained his MD at the Ludwig-Maximilian University in Munich and started his research career as a scholar of the Max-Planck Society and the Max-Kade Foundation in New York. He held several post-doctorate positions at leading academic institutions before becoming an entrepreneur.
Aside from his work in Precision Medicine
he developed a novel concept for value creation in research intensive industries; i.e. “Symbiotic Innovation”. With regard to this project Thomas is an associate at the GLORAD Research Center for Global R&D Management St. Gallen/Shanghai. Thomas is convinced that we will see a disruption of current diagnostics & therapeutic concepts and related business models. This paradigm shift will be induced by the advent of even greater communication and computing capabilities in concert with progress in omics and sensor technologies; i.e. Precision Medicine
will ultimately be supported by algorithms for prevention, diagnostics and therapeutic decision making and become available anywhere 24/7.